Pb1929: Efficacy and Safety of Acalabrutinib in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: An Open-Label, Multicenter Phase 1/2 Trial

Abstract

Background:Acalabrutinib (acala), a selective next-generation covalent Bruton tyrosine kinase inhibitor with minimal off-target activity, is approved in the United States and Europe for the treatment of chronic lymphocytic leukemia (CLL). The primary studies supporting the approval of acala in CLL were conducted predominantly in Europe and North America, with limited representation of Asian populations. This phase 1/2 study (NCT03932331) evaluated acala in Chinese patients (pts) with relapsed/refractory (R/R) CLL.